LAS 41001Alternative Names: LAS-41001
Latest Information Update: 14 Apr 2010
$50 / €47 *
At a glance
- Originator Laboratorios Almirall
- Developer Almirall S.A.
- Mechanism of Action Retinoic acid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rosacea
Most Recent Events
- 11 May 2009 Preregistration for Rosacea in European Union (PO)